China is inoculating tens of thousands of its citizens with experimental coronavirus vaccines and attracting international interest in their development, despite expert concerns over the safety of drugs that have not completed standard testing.
China launched a vaccine emergency use program in July, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and U.S.-listed Sinovac Biotech. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Aiming to protect essential workers and reduce the likelihood of a resurgence, the vaccines are also grabbing attention in the global scramble by governments to secure supplies, potentially helping reframe China's perceived role in the pandemic.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.